RxDoctor Payments Data

Brian Rebello, MD

Internal Medicine · Delray Beach, FLNPI 1497728877

Payments from drug & device makers

$8,248in general payments, 2019–2025

Across 315 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$933
  • Novo Nordisk$670
  • Lilly USA, LLC$635
  • Amarin Pharma, Inc.$605
  • AstraZeneca$562
  • Novartis$468
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,15699%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,248 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$858,537
Medicare patients
1,438
Services billed
16,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide201$299,217
EliquisApixaban208$235,792
RybelsusSemaglutide53$113,054
JardianceEmpagliflozin86$110,442
Repatha SureclickEvolocumab118$93,747
XareltoRivaroxaban78$89,205
MounjaroTirzepatide54$69,554
TrulicityDulaglutide35$50,068
JanuviaSitagliptin Phosphate52$47,348
CreonLipase/Protease/Amylase23$45,763
FarxigaDapagliflozin Propanediol21$24,288
UbrelvyUbrogepant17$21,477
ProliaDenosumab12$20,387
Breo ElliptaFluticasone/Vilanterol29$20,347
EntrestoSacubitril/Valsartan17$19,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$670$412,271254 claims
PfizerEliquis$129$235,792208 claims
Boehringer IngelheimJardiance, Tradjenta$21$119,68297 claims
Lilly USA, LLCMounjaro, Trulicity$635$119,62289 claims
AbbVieCreon, Ubrelvy, Linzess, Synthroid$933$96,830241 claims
Johnson & JohnsonXarelto$79$89,20578 claims
MerckJanuvia, Belsomra$305$57,10569 claims
AstraZenecaFarxiga$562$24,28821 claims
AmgenProlia$404$20,38712 claims
GSKBreo Ellipta$220$20,34729 claims
NovartisEntresto$468$19,10917 claims
Sumitomo Pharma America, Inc.Gemtesa$129$14,54211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →